{"id":44429,"date":"2022-05-27T14:01:35","date_gmt":"2022-05-27T12:01:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/"},"modified":"2022-05-27T14:01:35","modified_gmt":"2022-05-27T12:01:35","slug":"novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/","title":{"rendered":"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\nMercy Halo Data Demonstrates Promise of Novel Extracellular Vesicle Biomarker-Based Approach for Early Cancer Detection\n<\/p>\n<p>NATICK, Mass.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/asco?src=hash\" target=\"_blank\" rel=\"noopener\">#asco<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmercybio.com%2F&amp;esheet=52732382&amp;newsitemid=20220527005085&amp;lan=en-US&amp;anchor=Mercy+BioAnalytics%2C+Inc.&amp;index=1&amp;md5=f739efc95c7815e91ba767533fa75fe3\" rel=\"nofollow noopener\" shape=\"rect\">Mercy BioAnalytics, Inc.<\/a>, a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that the Mercy Halo Ovarian Cancer (OC) assay substantially outperformed CA125 when distinguishing patients with early-stage high-grade serious ovarian cancer (HGSOC) from women with benign conditions in a new study to be presented next week at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The assay uses a novel method of analyzing biomarkers based on individual extracellular vesicles (EVs).\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/5\/mercy-logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/21\/mercy-logo.jpg\"><\/a><\/p>\n<p>\n\u201cThese preliminary data suggest this approach may detect all stages of ovarian cancer with high sensitivity at a very high specificity and works equally well in both plasma and serum. Mercy\u2019s assay shows promise in improving on CA125 by distinguishing stage I\/II cancer from benign ovarian tumors and could have clinical utility for both early detection and surgical referral recommendation for benign and malignant ovarian tumors,\u201d said Christine D. Berg, M.D., retired Chief, Early Detection Research Group, National Institutes of Health.\n<\/p>\n<p>\nThe study, titled \u201cExtracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer,\u201d will be presented on Saturday, June 4, 2022, at ASCO by Daniel Gusenleitner, Ph.D., Head of Computational Biology for Mercy Bioanalytics (Abstract #5542).\n<\/p>\n<p>\nThe study found that the Mercy Halo OC assay:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDisplayed separation of HGSOC from benign adnexal masses and healthy controls that was superior to CA125.\n<\/li>\n<li>\nWhen run against a variety of off-target cancers and inflammatory conditions, in most instances, discriminated them from ovarian cancer.\n<\/li>\n<li>\nWhen run in paired serum and plasma samples, had highly correlated signals with virtually no bias, indicating the assay can be validated further in established blood biorepositories, which offers the potential to accelerate clinical study and development.\n<\/li>\n<\/ul>\n<p>\nHGSOC is the most aggressive of all ovarian cancers and accounts for up to 70 percent of all ovarian cancer cases. Nearly 50 percent of ovarian cancer is detected at stage III or stage IV with poor survival outcomes. Current surveillance methods, including CA125, a current standard of care for ovarian cancer diagnosis, and ultrasound, are not effective enough at detecting early-stage disease. Emerging methods for early cancer detection rely primarily on tumor DNA circulating in blood (ctDNA), which is scarce in early-stage cancers, costly to measure, and not reliably obtained from tumors that are not well vascularized.\n<\/p>\n<p>\nThe novel <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmercybio.com%2Fthe-mercy-halo-test%2F&amp;esheet=52732382&amp;newsitemid=20220527005085&amp;lan=en-US&amp;anchor=Mercy+Halo+technology&amp;index=2&amp;md5=8e6d1e84e84829d5e9303e3eaa581e4a\" rel=\"nofollow noopener\" shape=\"rect\">Mercy Halo technology<\/a> enables simultaneous detection of multiple cancer-related biomarkers co-localized on the surface of individual tumor-derived extracellular vesicles, which are abundant in circulation and can be readily measured. The Mercy Halo OC assay is designed to detect stage I\/II ovarian cancer and to distinguish cancer from benign conditions.\n<\/p>\n<p>\n\u201cToo many women today suffer, and ultimately lose their lives, as a result of the late detection of ovarian cancer. We are encouraged by the data of our most recent study comparing the Mercy Halo Ovarian Cancer assay to CA125 in detecting early-stage ovarian cancer and distinguishing it from benign disease,\u201d said Paul Blavin, Chief Executive Officer of Mercy BioAnalytics. \u201cOur unique approach, focused on co-localization to interrogate single extracellular vesicles, has important advantages over current early cancer detection methods, and our work thus far has fueled our passion for relieving suffering and saving lives through the early detection of cancer. We look forward to expanding our studies of the Mercy Halo Ovarian Cancer assay to include average risk, asymptomatic women who might benefit from an improved ovarian cancer screening paradigm.\u201d\n<\/p>\n<p>\n<b>ABOUT MERCY BIOANALYTICS, INC.<\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercybio.com%2F&amp;esheet=52732382&amp;newsitemid=20220527005085&amp;lan=en-US&amp;anchor=Mercy+BioAnalytics%2C+Inc.&amp;index=3&amp;md5=86c9568a7543704600a6b6abbb2a523b\" rel=\"nofollow noopener\" shape=\"rect\"><b>Mercy BioAnalytics, Inc.<\/b><\/a><b> is on a mission to relieve suffering and save lives through the early detection of cancer. <\/b>Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant blood-based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo platform is designed to detect stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy\u2019s initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast, prostate and colorectal cancers combined. For additional information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercybio.com%2F&amp;esheet=52732382&amp;newsitemid=20220527005085&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.mercybio.com&amp;index=4&amp;md5=75b0a32205fd98df914be416e523588f\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.mercybio.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMichelle McAdam, Chronic Communications Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#x6f;:&#x6d;&#105;&#x63;&#x68;e&#x6c;&#108;&#x65;&#x40;c&#x68;&#114;&#x6f;&#x6e;i&#x63;&#45;&#x63;&#x6f;m&#x6d;&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">m&#105;&#x63;&#x68;&#x65;l&#108;&#101;&#x40;&#x63;h&#114;&#111;&#x6e;&#x69;c-&#99;&#x6f;&#x6d;&#x6d;&#46;&#99;&#x6f;&#x6d;<\/a><br \/>310.902.1274\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mercy Halo Data Demonstrates Promise of Novel Extracellular Vesicle Biomarker-Based Approach for Early Cancer Detection NATICK, Mass.&#8211;(BUSINESS WIRE)&#8211;#asco&#8212;Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that the Mercy Halo Ovarian Cancer (OC) assay substantially outperformed CA125 when distinguishing patients with early-stage high-grade serious ovarian cancer &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-44429","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Mercy Halo Data Demonstrates Promise of Novel Extracellular Vesicle Biomarker-Based Approach for Early Cancer Detection NATICK, Mass.&#8211;(BUSINESS WIRE)&#8211;#asco&#8212;Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that the Mercy Halo Ovarian Cancer (OC) assay substantially outperformed CA125 when distinguishing patients with early-stage high-grade serious ovarian cancer ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-27T12:01:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/21\/mercy-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting\",\"datePublished\":\"2022-05-27T12:01:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/\"},\"wordCount\":757,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005085\\\/en\\\/1469120\\\/21\\\/mercy-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/\",\"name\":\"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005085\\\/en\\\/1469120\\\/21\\\/mercy-logo.jpg\",\"datePublished\":\"2022-05-27T12:01:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005085\\\/en\\\/1469120\\\/21\\\/mercy-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005085\\\/en\\\/1469120\\\/21\\\/mercy-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting - Pharma Trend","og_description":"Mercy Halo Data Demonstrates Promise of Novel Extracellular Vesicle Biomarker-Based Approach for Early Cancer Detection NATICK, Mass.&#8211;(BUSINESS WIRE)&#8211;#asco&#8212;Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that the Mercy Halo Ovarian Cancer (OC) assay substantially outperformed CA125 when distinguishing patients with early-stage high-grade serious ovarian cancer ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-27T12:01:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/21\/mercy-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting","datePublished":"2022-05-27T12:01:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/"},"wordCount":757,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/21\/mercy-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/","name":"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/21\/mercy-logo.jpg","datePublished":"2022-05-27T12:01:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/21\/mercy-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220527005085\/en\/1469120\/21\/mercy-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/novel-assay-for-early-detection-of-ovarian-cancer-from-mercy-bioanalytics-significantly-outperforms-ca125-in-new-research-presented-at-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44429"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44429\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}